Today in New York, the Clinton Global Initiative (CGI) recognized AREVA and its subsidiary AREVA Med LLC for its pioneering work in developing new methods for producing medical-grade Lead 212─ a promising isotope for combating cancer.
As the world leader in clean energy generation, AREVA has rather unique expertise in radiochemistry and nuclear engineering that now we are using to help devise new ways to extract rare isotopes.
AREVA Med President Patrick Bourdet said, “Now that the project has reached important scientific and technical milestones, we are excited to share our optimism about our work. We are committed to the possibility that we can combat cancer with innovative new treatments, and the production of medical-grade lead 212 is a major step forward. We are honored by this recognition by the prestigious Clinton Global Initiative.”
This recognition by the CGI is also an acknowledgement of the work done in cooperation with our remarkable partners, the U.S. National Cancer Institute and the University of Alabama at Birmingham.
Find out more information on AREVA Med LLC here.
And this is the second year in a row that AREVA has been recognized by the CGI. Last year ADAGE, our joint-venture with Duke Energy to build biomass plants, was spotlighted.
Posted in: Nuclear Energy, Nuclear Medicine | View Comments